Abstract
Inodilators are a heterogeneous group of drugs with vasodilatory and inotropic effects. The cardioprotective effect of levosimendan is multifactorial, but now research on levosimendan is focused on the organ-protective properties of this drug in different settings, the regimen that seems to provide the greatest cardiologic and systemic benefits is early administration of levosimendan. We try to answer four questions in this review, which type of patients need this drug? what is the best time to start with it? and the best way that we could give it and finally the reasons for use it.
Keywords: Levosimendan, preconditioning, postconditioning, mechanisms, cardiac surgery, calcium sensitizers.
Current Vascular Pharmacology
Title:Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Volume: 16 Issue: 4
Author(s): J.L. Guerrero Orriach*, A. Ramirez-Fernandez, J.J. Escalona-Belmonte , M. Rubio-Navarro and J. Cruz-Manas
Affiliation:
- Department of Cardio-Anaesthesiology, Virgen de la Victoria University Hospital, Malaga,Spain
Keywords: Levosimendan, preconditioning, postconditioning, mechanisms, cardiac surgery, calcium sensitizers.
Abstract: Inodilators are a heterogeneous group of drugs with vasodilatory and inotropic effects. The cardioprotective effect of levosimendan is multifactorial, but now research on levosimendan is focused on the organ-protective properties of this drug in different settings, the regimen that seems to provide the greatest cardiologic and systemic benefits is early administration of levosimendan. We try to answer four questions in this review, which type of patients need this drug? what is the best time to start with it? and the best way that we could give it and finally the reasons for use it.
Export Options
About this article
Cite this article as:
Orriach Guerrero J.L. *, Ramirez-Fernandez A., Escalona-Belmonte J.J., Rubio-Navarro M. and Cruz-Manas J., Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?, Current Vascular Pharmacology 2018; 16 (4) . https://dx.doi.org/10.2174/1570161115666171116150434
DOI https://dx.doi.org/10.2174/1570161115666171116150434 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Current Biology of MTP: Implications for Selective Inhibition
Current Topics in Medicinal Chemistry Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease
Current Vascular Pharmacology Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Current Medicinal Chemistry Antibacterial and Antioxidant Property of Streptomyces cinnamonensis VITNS1 Isolated from Serkadu Region, Vellore, Tamil Nadu, India
Anti-Infective Agents Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics Production of Fibrinolytic Protease from a Halobacterium <i>Bacillus licheniformis</i> VITLMS Isolated from Marine Sponges of Rameshwaram Coast, India
Current Bioactive Compounds Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design